Molecular heterogeneity in medulloblastoma with implications for differing tumor biology

Journal of Child Neurology

Volumn 14, Issue 7, 1999, Pages 411-417

  Adesina, Adekunle M ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CALBINDIN; CALPHOSTIN C; CYCLINE; DIACYLGLYCEROL; DNA; ENZYME INHIBITOR; GENE PRODUCT; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR; PHORBOL ESTER; PHOSPHOLIPID; PHOSPHOTRANSFERASE; PROTEIN KINASE C; PROTEIN P53; PROTEIN SERINE KINASE;

APOPTOSIS; CELL CYCLE; CELL HETEROGENEITY; GENE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR DIFFERENTIATION;

EID: 0032781682     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307389901400701     Document Type: Review

References (78)

1. Russell DS, Rubinstein LJ: Pathology of Tumor's of the Central Nervous system, 5th ed. Baltimore, Williams & Wilkins, 1989, pp 251-270.
2. Bailey P, Cushing H: Medulloblastoma cerebelli; a common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry 1925;14:192.
3. Rorke LB, Gilles FH, Davis RL, et al: Revision of the World Health Organization classification of brain tumors for childhood brain tumors. Cancer 1985;56:1869-1886.
4. Yachnis AT, Rocke LB, Lee VM-Y, et al: Expression of neuronal and glial polypeptides during histogenesis of the human cerebellar cortex including observations on the dentate nucleus. J Comp Neurol 1993;334:356-369.
5. Jessel TM: Neuronal survival and synapse formation, in Kandel ER, Schwartz JH, Jessell TM (eds): Principles of Neural Science. New York, Elsevier, 1991, pp 929-944.
6. Katsetos CD, Burger PC: Medulloblastoma. Sem in Diagn Pathol 1994;11:85-97.
7. 28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol 1993;52:655-666.
8. Vinores SDA, Herman MM, Katsetos CD, et al: Neuron associated class III β tubulin, tau and MAP2 in the D283-Med cell line and in primary explants of human medulloblastoma. Histochem J 1994;26: 678-685.
9. Trojanowski JQ, Tohyama T, Lee VM-Y: Medulloblastoma and related primitive neuroectodermal tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. Mol Chem Neuropathol 1992;17:121-135.
10. Bigner SH, Mark J, Friedman HS, et al: Structural chromosomal abnormalities in human medulloblastoma Cancer Genet Cytogenet 1988;30:91-101.
11. James CD, Ju HE, Carlbom E, et al: Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer 1990;2:94-102.
12. Cogen PH, Daneshvar L, Metzger AK, et al: Involvement of multiple 17p loci in medulloblastoma tumorigenesis. Am J Hum Genet 1992;50:584-689.
13. Biegel JA, Burk CD, Barr FG, et al: Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992;52:3391-3395.
14. Thomas GA, Raffel C: Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors. Cancer Res 1991;51:639-643.
15. Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994;54:5649-5651.
16. Saylors III RL, Sidransky D, Friedman HS, et al: Infrequent p53 gene mutations in medulloblastomas. Cancer Res 1991;51:4721-4723.
17. Batra SK, McLendon RE, Koo JS, et al: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45.
18. Kraus JA, Koch A, Albretcht S, et al: Loss of heterozygosity at locus F13B on chromosome Iq in human medulloblastoma. Int J Cancer 1996;67:11-15.
19. Schofield D, West Anthony DC, Marshal R, et al: Correlation of loss of heterozygosity at chromosome 9q with histologic subtype in medulloblastomas. Am J Pathol 1995;146:472-480.
20. Bale AE: The nevoicl basal cell carcinoma syndrome: Genetics and mechanisms of carcinogenesis. Cancer Invest 1997;15:180-186.
21. Raffel C, Jenkins RB, Frederick L, et al: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-845.
22. Vorechovsky I, Tingby O, Hartman M, et al: Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumors. Oncogene 1997;15:361-366.
23. Reifenberger J, Wolter M, Weber EG, et al: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58:1798-1803.
24. Pietsh T, Waha A, Koch A, et al: Medulloblastomas of the desmo-plastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997;57:2085-2088.
25. Shafei-Benaissa E, Savage JR, Babin P, et al: The nevoid basal cell carcinoma syndrome (Gorlin syndrome) is a chromosomal instability syndrome. Mutal Res 1998;397:287-292.
26. Goodrich LV, Milenkovic L, Higgins KM, et al: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-1113.
27. Hamilton SR, Liu B, Parsons RE, et al: The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-849.
28. Mori T, Nagase H, Horrii A, et al: Germline and somatic mutations of the APC gene with Turcot's syndrome and analysis of APC mutation in brain tumors. Genes Chromosomes Cancer 1994;9:168-172.
29. MacGregor DN, Ziff EB: Elevated c-myc expression in childhood medulloblastomas. Pediatr Res 1990;28:63-68.
30. Wasson JC, Saylors III RL, Zelter P, et al: Oncogene amplification in pediatric brain tumors. Cancer Res 1990;50:2987-2990.
31. Bigner SH, Friedman SH, Vogelstein B, et al: Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-2350.
32. Garson JA, Pemberton LF, Sheppard PW, et al: N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br J Cancer 1989;59:889-894.
33. Fults D, Maness PF, Nakamura Y, et al: The N-ras oncogene is activated in a human medulloblastoma cell line. Brain Res 1989;503: 281-287.
34. Gilbertson RJ, Pearson ADJ, Peryy RH, et al: Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-477.
35. Ben-Ari Y, Anikszteijn L, Biegestovki P: Protein kinase C modulation of NMDA currents: An important link for LTP induction. Trends Neurosci 1992;15:333-339.
36. Saito N, Kikkawa U, Nishizuka Y, et al: Distribution of protein kinase C-like immunoreactive neurons in rat brain. J Neurosci 1988;8:369-382.
37. Koda Y, Kobayashi H, Mizki T, et al: Protein kinase C subtypes in tissues derived from neural crest. Brain Res 1990;518:334-336.
38. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-613.
39. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334: 661-665.
40. Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995;9:484-496.
41. Ghosh S, Baltimore D: Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990;344:678-682.
42. Kolch W, Heidecker G, Kochs G, et al: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993;364:249-252.
43. Youg SW, Dickens M, Tavare JM: Activation of mitogen-activated protein kinase by protein kinase C isotypes alpha, beta 1 and gamma but not epsilon. FEBS Lett 196;384:181-184.
44. Baltuch GH, Dooley NP, Rostworowski KM, et al: Protein kinase C isoform α overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 1995;24:241-250.
45. Mischak H, Pierce JH, Goodnight J, et al: Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-α and -δ and not by protein kinase C-βII, -ε, -ζ, -η. J Biol Chem 1993;268: 20110-20115.
46. Watanabe T, Ono Y, Taniyama Y, et al: Cell division arrest induced by phorbol ester in CHO overexpressing protein kinase C-δ subspecies. Proc Natl Acad Sci USA 1992;89:10159-10163.
47. Zhou W, Takuwa N, Kumada M, et al: Protein kinase C-mediated bidirectional regulation of DNA synthesis, RB protein phosphorylation and cyclin dependent kinases in human vascular endothelial cells. J Biol Chem 1993;268:23041-23048.
48. 1->S cell cycle transition. Cell Growth Differ 1996;7: 75-81.
49. Holgado-Madruga M, Emlet DR, Moscatello DK, et al: A Grb2-associated docking protein in EGF and insulin receptor signaling. Nature 1996;379:560-564.
50. Segal RA, Goumnerova LC, Kwon YK, et al: Expression of neurotrophin receptor trk C is linked to a favorable outcome in medulloblastoma.Proc Natl Acad Sci USA 1994;91:12867-12871.
51. Adesina AM, Dooley N, Yong V-W, et al: Differential role for protein kinase C-mediated signaling in the proliferation of medulloblastoma cell lines. Int. J Oncol 1998;12:759-768.
52. Eldar H, Zisman Y, Ullrich A, et al: Overexpression of protein kinase C a subtype in Swiss/3T3 fibroblasts causes loss of both high and low affinity receptor numbers for epidermal growth factor. J Biol Chem 1990;265:13290-13296.
53. Capdevila J, Tabin C, Johnson RL: Control of dorsoventral patterning by wnt-1 and beta-catenin. Dev Biol 1998;193:182-194.
54. Pennisi E: How a growth control path takes a wrong turn to cancer. Science 1998;281:1438-1441.
55. Behrens J, Jerchow BA, Wurtele M, et al: Functional interaction of an axin homolog, conductin, with beta catenin, APC, and GSK3beta. Science 1998;280:596-599.
56. He T-C, Sparks AB, Rago C, et al: Identification of c-myc as a target of the APC pathway. Science 1998;281:1509-1512.
57. Zurawel RH, Chiappa SA, Allen C, et al: Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58: 896-899.
58. Liu M, Lee M-H, Cohen M, et al: Transcriptional activation of the cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10: 142-153.
59. Parker SB, Eichele G, Zhang P, et al: p53 independent expression of p21/cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-1027.
60. Gartel AL, Serfas MS, Gartel M, et al: p21 (waf1/cip1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 1996;227:171-181.
61. waf1/cip1 expression in normal mucosa and in adenoma and adenocarcinoma of the colon: Its relationship with differentiation. J Pathol 1993;179:248-253.
62. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
63. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
64. 1 cyclin-dependent kinases. Cell 1993;75:805-816.
65. Lee MH, Nikolic M, Baptista CA, et al: The brain specific activator p35 allows cdk5 to escape inhibition by p27kipl in neurons. Proc Natl Acad Sci USA 1996;93:3259-3263.
66. Ponce-Castaneda MV, Lee MH, Latres E, et al: p27kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-1214.
67. Spirin KS, Simpso JF, Takeuchi S, et al: p27/kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-2404.
68. Orlow I, lavarone A, Crider-Milner SJ, et al: Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Res 1996;56:1219-1221.
69. Mousses S, Ozcelik H, Lee PD, et al: Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995;4:1089-1092.
70. He X, Med MS, Skapek SX, et al: Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 1989;48:48-68.
71. Adesina AM, Dunn T, Nalbantoglu J: The pattern of p27kip1 expression shows a correlation between focal inhibition of proliferation and differentiation in medulloblastoma, abstract. J Neuropathol Exp Neurol 1998;57:521.
72. Fer ML, Rivkin M, Tasch M, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27(kip1)-deficient mice. Cell 1996;85:733-744.
73. Barker FG, Chen P, Furman F, et al: p16 deletion and mutation analysis in human brain tumors. J Neurooncol 1974;31:17-23.
74. Nakamura T, Takeshita I, Inamure T, et al: Expression of a chain of platelet, derived growth factor and proliferative activity of human brain tumors. Neurol Med Chir (Tokyo) 1993;33:205-211.
75. Jennings MT, Kaariainen IT, Gold L, et al: TGB beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors and ependymomas: Evidence in support of an autocrine hypothesis. Hum Pathol 1994;25:464-475.
76. Stockhammer G, Manley GT, Johnson R, et al: Inhibition of proliferation and induction of differentiation in medulloblastoma and astrocytoma derived cell lines with phenylacetate. J Neurosurgery 1995;83:672-681.
77. Sure U, Berghoom WJ, Bertalanffy H, et al: Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases from a single institute. Acta Neurochir (Wien) 1995;132:59-65.
78. Albright AL, Wisoff JH, Zelter PM, et al: Effects of medulloblastoma resection on outcome in children: A report: from the children's cancer group. Neurosurgery 1996;38:265-271.